Drug	Schedule
Lysergic acid diethylamide (7315).	I
Marihuana (7360)	1
Tetrahydrocannabinols (7370)	1
Mescaline (7381)	1
Bufotenine (7433)	1
Etonitazene (9624)	1
Methylphenidate (1724)	II
Secobarbital (2315)	l II
Glutethimide (2550)	l II
Diprenorphine (9058)	H
Oxycodone (9143)	!!
Hydromorphone (9150)	!!
Diphenoxylate (9170)	!!
Hydrocodone (9193)	!!
Levomethorphan (9210)	l II
Levorphanol (9220)	!!
Meperidine (9230)	!!
Metazocine (9240)	
Methadone (9250)	
Dextropropoxyphene, bulk (non-dosage forms) (9273).	II
Thebaine (9333)	l II
Levo-alphacetylmethadol (LAAM) (9648).	Ш
Oxymorphone (9652)	II

The firm plans to import small quantities of the listed controlled substances to manufacture laboratory reference standards and neurochemicals.

No comments or objections have been received. DEA has considered the factors in title 21, United States Code, Section 823(a) and determined that the registration of Research Biochemicals to import the listed controlled substances is consistent with the public interest and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971, at this time. DEA has investigated Research Biochemicals on a regular basis to ensure that the company's continued registration is consistent with the public interest. These investigations have included inspection and testing of the company's physical security systems, audits of the company's records, verification of the company's compliance with state and local laws, and a review of the company's background and history. Therefore, pursuant to Section 1008(a) of the Controlled Substances Import and Export Act and in accordance with Title 21, Code of Federal Regulations, Section 1301.34, the above firm is granted registration as an importer of the basic classes of controlled substances listed above.

Dated: August 5, 1999.

John H. King,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. 99–21585 Filed 8–19–99; 8:45 am] BILLING CODE 4410–09–M

DEPARTMENT OF JUSTICE

Drug Enforcement Administration [DEA #179S2]

Controlled Substances: 1999 Aggregate Production Quota

AGENCY: Drug Enforcement Administration, (DEA), Justice.

ACTION: Final interim notice establishing a revised 1999 aggregate production quota.

SUMMARY: The interim notice 64 FR 29358, June 1, 1999, which revised the 1999 aggregate production quota for secobarbital, a Schedule II controlled substance in the Controlled Substances Act (CSA), is adopted without change. **DATES:** This is effective on August 20, 1999

FOR FURTHER INFORMATION CONTACT: Frank L. Sapienza, Chief, Drug and Chemical Evaluation Section, Drug Enforcement Administration,

Enforcement Administration, Washington, D.C. 20537, Telephone: (202) 307–7183.

SUPPLEMENTARY INFORMATION: Section 306 of the CSA (21 U.S.C. 826) requires that the Attorney General establish aggregate production quotas for each basic class of controlled substance listed in Schedules I and II each year. This responsibility has been delegated to the Administrator of the DEA by Section 0.100 of Title 28 of the Code of Federal Regulations. The Administrator, in turn, has redelagated this function to the Deputy Administrator of the DEA pursuant to Section 0.104 of Title 28 of the Code of Federal Regulations.

On June 1, 1999, an interim notice establishing a revised 1999 aggregate production quota for secobarbital was published in the **Federal Register** (64 FR 29358). All interested persons were invited to comment on or before July 1, 1999. No comments or objections were received and the interim notice is adopted without change.

Therefore, under the authority vested in the Attorney General by Section 306 of the CSA (21 U.S.C. 826), delegated to the Administrator of the DEA by Section 0.100 of Title 28 of the Code of Federal Regulations, and redelegated to the Deputy Administrator, pursuant to § 0.104 of Title 28 of the Code of Federal Regulations, the Deputy Administration hereby establishes the following revised 1999 aggregate production quota for the listed controlled substances, expressed in grams of anhydrous acid:

Basic class	Revised 1999 quota
Secobarbital	1,011,000

The Office of Management and Budget has determined that notices of aggregate production quotas are not subject to centralized review under Executive Order 12866. This action has been analyzed in accordance with the principles and criteria contained in Executive Order 12612, and it has been determined that this matter does not have sufficient federalism implications to warrant the preparation of a Federalism Assessment.

The Deputy Administrator hereby certifies that this action will have no significant impact upon small entities whose interests must be considered under the Regulatory Flexibility Act, 5 U.S.C. 601 et seq. The establishment of aggregate production quotas for Schedules I and II controlled substances is mandated by law and by international treaty obligations. The quotas are necessary to provide for the estimated medical, scientific, research and industrial needs of the United States, for export requirements and the establishment and maintenance of reserve stocks. While aggregate production quotas are of primarily importance to large manufacturers, their impact upon small entities is neither negative nor beneficial. Further, this action involves only one basic class of controlled substance. Accordingly, the Deputy Administrator has determined that this action does not require a regulatory flexibility analysis.

Dated: August 11, 1999.

Donnie R. Marshall,

Deputy Administrator.

[FR Doc. 99–21582 Filed 8–19–99; 8:45 am] BILLING CODE 4410–09–M

DEPARTMENT OF JUSTICE

Drug Enforcement Administration [DEA #179R]

Controlled Substances: Proposed Revised Aggregate Production Quotas for 1999

AGENCY: Drug Enforcement Administration (DEA), Justice. ACTION: Notice of proposed revised 1999 aggregate production quotas.

SUMMARY: This notice proposes revised 1999 aggregate production quotas for controlled substances in Schedule I and II of the Controlled Substances Act (CSA).

DATES: Comments or objections must be received on or before September 20, 1999.

ADDRESSES: Send comments or objections to the Deputy Administrator,